Skip to main content
. 2019 Oct 1;8(10):1565. doi: 10.3390/jcm8101565

Figure 1.

Figure 1

Improvements in the tricuspid regurgitant jet velocity (TRJV) after hematopoietic stem cell transplantation in adults with sickle cell disease from (A) the National Institutes of Health (n = 13) and (B) University of Illinois at Chicago (pre-HSCT mean = 2.3 ± 0.5 m/s, post-HSCT mean = 2.0 ± 0.4 m/s) (n = 12) cohorts, using an alemtuzumab and total body irradiation conditioning regimen.